COSMO Pharmaceuticals N.V. (0RGI) Share Price & Analysis

15 Followers

0RGI Stock Chart & Stats

CHF 58.55CHF 1.15(2.00%)

At close: Nov 12 4:30 PM GMT

Day’s Range: CHF 57.40 - CHF 59.60
52-Week Range: CHF 49.20 - CHF 129.60
Previous Close: CHF 57.40
Volume: N/A
Average Volume (3M): 2,360
Market Cap: CHF 966.49M
Enterprise Value: CHF 963.95M
Total Cash (Recent Filing): CHF 195.28M
Total Debt (Recent Filing): CHF 4.33M
Price to Earnings (P/E): ―
Beta: 1.27
Next Earnings: Mar 24, 2027 (Est.)
EPS Estimate: N/A
Last Dividend Ex-Date: Apr 24, 2026
Dividend Yield: 3.29%

Bulls Say, Bears Say

Bulls Say

Conservative Balance Sheet

Very low leverage and substantial equity provide financial resilience and flexibility while the company works through operating volatility. This reduces reliance on borrowing, limits interest-related pressure, and leaves greater capacity to fund products, partnerships, or recovery initiatives.

Diversified Revenue Model

Combining proprietary product sales with licensing, milestones, royalties, and potential partner supply revenue creates several monetization routes. This model can broaden commercial reach and allow COSMO to capture value from its products and technologies across territories.

Demonstrated Profit And Cash Generation

The exceptional 2024 results show that COSMO has previously converted commercial activity into substantial earnings and cash generation. That demonstrated operating potential supports the case for meaningful earnings power if product performance and partnerships recover.

Bears Say

Sharp Revenue Contraction

The steep year-over-year revenue decline indicates that the latest business run-rate is materially weaker than the prior year. A smaller revenue base can reduce operating leverage, limit reinvestment capacity, and make future earnings more dependent on successful product or partnership execution.

Negative Cash Generation

Turning from strong cash generation to operating and free cash outflow weakens the company’s ability to self-fund ongoing activities. Although the balance sheet is conservative, sustained cash burn could reduce financial flexibility and increase dependence on existing reserves or future financing.

Volatile Profitability

Profitability has varied sharply across years, with losses in multiple periods and a negative 2025 result after an exceptional 2024. This inconsistency reduces earnings visibility, complicates planning, and makes it harder to assess the sustainable level of operating returns.

COSMO Pharmaceuticals N.V. News

Cosmo’s Rifamycin Gel Hits Key Phase 2 Mark in Distal Ulcerative Colitis

COSMO Pharmaceuticals N.V. ( ($CH:CMHC) ) just unveiled an update. Cosmo Pharmaceuticals N.V., a specialty drugmaker in gastrointestinal diseases, is advancing novel locally acting therapies using proprietary liquid‑to‑gel delivery systems

3w agoCMOPF C43

Cosmo’s GI Genius AI System Boosts Adenoma Detection in Major VA Study

COSMO Pharmaceuticals N.V. ( ($CH:CMHC) ) has shared an update. Cosmo has reported landmark real-world results for its GI Genius intelligent endoscopy platform from the CADeNCE study in U.S. Veterans

1M agoCMOPF C43

Cosmo Pharmaceuticals to Change SIX Ticker to CMHC, Aligning Brand With Health-Focused Strategy

COSMO Pharmaceuticals N.V. ( ($CH:COPN) ) has provided an announcement. Cosmo Pharmaceuticals N.V. will change its ticker symbol on SIX Swiss Exchange from COPN to CMHC, effective at the start

3M agoCMOPF C43

Cosmo lifts recurring revenues and advances dermatology and GI pipelines

COSMO Pharmaceuticals N.V. ( ($CH:COPN) ) just unveiled an announcement. Cosmo reported strong first-half 2026 results, with recurring revenues up 18% year-on-year, driven by 38% growth from Winlevi, 35% from

3M agoCMOPF C43

Cosmo sets date for 2026 half-year results and investor webcast

COSMO Pharmaceuticals N.V. ( ($CH:COPN) ) has issued an announcement. Cosmo Pharmaceuticals will publish its 2026 half-year results and report on 23 July, with the documents available online from early

4M agoCMOPF C43

Cosmo accelerates European rollout of first-in-class acne drug Winlevi

COSMO Pharmaceuticals N.V. ( ($CH:COPN) ) has issued an update. Cosmo Pharmaceuticals has expanded the European rollout of its acne treatment Winlevi, with market launches in Austria and Germany via

5M agoCMOPF C43

Cosmo and Glenmark roll out first-in-class acne drug Winlevi across key European markets

COSMO Pharmaceuticals N.V. ( ($CH:COPN) ) has shared an announcement. Cosmo Pharmaceuticals’ dermatology unit Cassiopea has developed Winlevi, a first-in-class topical acne therapy based on the androgen receptor inhibitor clascoterone,

5M agoCMOPF C43

Cosmo completes Phase II recruitment for novel ulcerative colitis therapy

COSMO Pharmaceuticals N.V. ( ($CH:COPN) ) just unveiled an announcement. Cosmo Pharmaceuticals has completed patient recruitment for a Phase II trial of its Rifamycin enema, an investigational treatment for distal

5M agoCMOPF C43

Cosmo price target raised to CHF 160 from CHF 130 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Cosmo Pharmaceuticals (CMOPF) to CHF 160 from CHF 130 and keeps a Buy rating on the shares. The firm cites the addition

6M agoCMOPF C43

Cosmo’s Clascoterone Delivers Strong 12‑Month Data in Male Hair Loss, Paving Way for 2027 Filings

COSMO Pharmaceuticals N.V. ( ($CH:COPN) ) just unveiled an announcement. Cosmo Pharmaceuticals has reported positive 12‑month Phase III data for its Clascoterone 5% topical solution in men with mild to

7M agoCMOPF C43

Cosmo Shareholders Approve All AGM Resolutions and EUR 2.10 Dividend

COSMO Pharmaceuticals N.V. ( ($CH:COPN) ) has shared an announcement. Cosmo Pharmaceuticals reported that shareholders approved all agenda items at the 2026 Annual General Meeting, with 59.02% of outstanding ordinary

7M agoCMOPF C43

0RGI FAQ

What was COSMO Pharmaceuticals N.V.’s price range in the past 12 months?

COSMO Pharmaceuticals N.V. lowest share price was CHF49.20 and its highest was CHF129.60 in the past 12 months.

What is COSMO Pharmaceuticals N.V.’s market cap?

COSMO Pharmaceuticals N.V.’s market cap is CHF966.49M.

When is COSMO Pharmaceuticals N.V.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were COSMO Pharmaceuticals N.V.’s earnings last quarter?

COSMO Pharmaceuticals N.V. released its earnings results on Jul 23, 2026. The company reported -CHF0.263 earnings per share for the quarter, missing the consensus estimate of CHF0 by -CHF0.263.

Is COSMO Pharmaceuticals N.V. overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does COSMO Pharmaceuticals N.V. pay dividends?

COSMO Pharmaceuticals N.V. pays an annual dividend of CHF1.928 which represents an annual dividend yield of 3.29%. See more information on COSMO Pharmaceuticals N.V. dividends here

What is COSMO Pharmaceuticals N.V.’s EPS estimate?

COSMO Pharmaceuticals N.V.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does COSMO Pharmaceuticals N.V. have?

COSMO Pharmaceuticals N.V. has 17,543,522 shares outstanding.

What happened to COSMO Pharmaceuticals N.V.’s price movement after its last earnings report?

COSMO Pharmaceuticals N.V. reported an EPS of -CHF0.263 in its last earnings report, missing expectations of CHF0. Following the earnings report the stock price went up 7.194%.

Which hedge fund is a major shareholder of COSMO Pharmaceuticals N.V.?

Currently, no hedge funds are holding shares in GB:0RGI

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description